GT 102279

Drug Profile

GT 102279

Latest Information Update: 08 Feb 2008

Price : $50

At a glance

  • Originator GelTex Pharmaceuticals
  • Developer GelTex Pharmaceuticals; Sankyo
  • Class Antihyperlipidaemics
  • Mechanism of Action Bile acid binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 16 Feb 2006 No development reported - Preclinical for Hypercholesterolaemia in Japan (PO)
  • 18 Feb 2003 Discontinued - Phase-II for Hypercholesterolaemia in USA (PO)
  • 13 Jun 2002 Preclinical trials in Hypercholesterolaemia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top